Millennium extends collaboration

MLNM extended for an additional year a 1997 deal with Kyowa Hakko Kogyo (Tokyo, Japan) to develop and discover treatments for inflammatory and autoimmune diseases based on MLNM's chemokine receptors found on leukocytes. The three-year agreement was originally between Kyowa Hakko and LeukoSite, which MLNM acquired.

In addition to research funding and milestones, MLNM will receive licensing fees and royalties on resulting products. Kyowa Hakko has Asian marketing rights, and Warner-Lambert (WLA) has an option to market products elsewhere. ...